In-vitro evaluation of the P-glycoprotein interactions of a series of potentially CNS-active Amaryllidaceae alkaloids

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 11, 2012, Pages 1667-1677

  Eriksson, André Huss ^a,b   Rønsted, Nina ^a   Güler, Semiha ^a   Jäger, Anna Katharina ^a   Sendra, Júlia Rodríguez ^a   Brodin, Birger ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b LEO PHARMA A S   (Denmark)

Author keywords

alkaloids; amaryllidaceae; calcein AM, MDCK(II) MDR1; P glycoprotein

Indexed keywords

1 EPI DEACETYLBOWDENISINE; 3 O ACETYLHAMAYNE; 6 HYDROXYCRINAMINE; ACETYLCHOLINESTERASE; ALKALOID; CALCEIN; CARRIER PROTEIN; CRININE; EPIBUPHANISINE; GALANTAMINE; LYCORINE; MULTIDRUG RESISTANCE PROTEIN 1; PAPYRAMINE; POWELLINE; SEROTONIN REUPTAKE TRANSPORTER; UNCLASSIFIED DRUG;

AMARYLLIDACEAE; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; DRUG DETERMINATION; DRUG STRUCTURE; ENZYME ASSAY; GENETIC TRANSFECTION; IC 50; IN VITRO STUDY; KIDNEY CELL; NONHUMAN;

AMARYLLIDACEAE ALKALOIDS; ANIMALS; BLOOD-BRAIN BARRIER; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEINS; FLUORESCENT DYES; HISTORY, ANCIENT; HUMANS; INHIBITORY CONCENTRATION 50; P-GLYCOPROTEIN; TRANSFECTION;

EID: 84867578859     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01536.x     Document Type: Article

References (38)

1. Stafford GI, et al,. Review on plants with CNS-effects used in traditional South African medicine against mental diseases. J Ethnopharmacol 2008; 119: 513-537.
2. Heinrich M, Teoh HL,. Galanthamine from snowdrop-the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J Ethnopharmacol 2004; 92: 147-162.
3. Maelicke A, et al,. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-288.
4. Jin Z,. Amaryllidaceae and Sceletium alkaloids. Nat Prod Rep 2009; 26: 363-381.
5. Elgorashi EE, et al,. Acetylcholinesterase enzyme inhibitory effects of Amaryllidaceae alkaloids. Planta Med 2004; 70: 260-262.
6. Lõpez S, et al,. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sci 2002; 71: 2521-2529.
7. Elgorashi EE, et al,. Inhibition of [3H]citalopram binding to the rat brain serotonin transporter by Amaryllidaceae alkaloids. Planta Med 2006; 72: 470-473.
8. Neergaard JS, et al,. Alkaloids from Boophone disticha with affinity to the serotonin transporter. S Afr J Bot 2009; 75: 371-374.
9. Farlow MR,. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 2003; 42: 1383-1392.
10. Butler MJ, Meegan MJ,. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter. Curr Med Chem 2008; 15: 1737-1761.
11. Loy C, Schneider L,. Galantamine for Alzheimer's disease and mild cognitive impairment (Review). Cochrane Database Syst Rev 2006; (1): CD001747.
12. Geerts H, et al,. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 2005; 1033: 186-193.
13. Tsinman O, et al,. Physicochemical selectivity of the BBB microenvironment governing passive diffusion-matching with a porcine brain lipid extract artificial membrane permeability model. Pharm Res 2011; 28: 337-363.
14. Pardridge WM,. Blood-brain barrier delivery. Drug Discov Today 2007; 12: 54-61.
15. Pajouhesh H, Lenz GR,. Medicinal chemical properties of successful central nervous system drugs. NeuroRX 2005; 2: 541-553.
16. Schinkel AH,. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999; 36: 179-194.
17. Li WX, et al,. Significance analysis and multiple pharmacophore models for differentiating P-glycoprotein substrates. J Chem Inf Model 2007; 47: 2429-2438.
18. Hayeshi R, et al,. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci 2006; 29: 70-81.
19. Madgula VLM, et al,. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability. Planta Med 2007; 73: 330-335.
20. Madgula VML, et al,. Intestinal and blood-brain barrier permeability of ginkgolides and bilobalide: in vitro and in vivo approaches. Planta Med 2010; 76: 599-606.
21. Sheu M-T, et al,. A quantitative structure-activity relationship for the modulation effects of flavonoids on P-glycoprotein-mediated transport. Chem Pharm Bull 2010; 58: 1187-1194.
22. Larsson J, et al,. ChemGPS-NP: tuned for navigation in biologically relevant chemical space. J Nat Prod 2007; 70: 789-794.
23. Keogh JP, Kunta JR,. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 2006; 27: 543-554.
24. Namanja HA, et al,. Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. Biochem Biophys Res Commun 2009; 388: 672-676.
25. Bakos E, et al,. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 1998; 273: 32167-32175.
26. Polli JW, et al,. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 2001; 299: 620-628.
27. Elgorashi EE, et al,. Alkaloids from Crinum bulbispermum. Phytochemistry 1999; 53: 533-536.
28. Elgorashi EE, et al,. Alkaloids from Crinum moorei. Phytochemistry 2001; 56: 637-640.
29. Elgorashi EE, van Staden J,. Alkaloids from Cyrtanthus falcatus. S Afr J Bot 2003; 69: 593-594.
30. Rautio J, et al,. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 2006; 34: 786-792.
31. Feng B, et al,. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 2008; 36: 268-275.
32. Bay-Smidt MGK, et al,. Phylogenetic selection of target species in Amaryllidaceae tribe Haemantheae for acetylcholinesterase inhibition and affinity to the serotonin reuptake transport protein. S Afr J Bot 2011; 77: 175-183.
33. Larsen MM, et al,. Using a phylogenetic approach to selection of target plants in drug discovery of acetylcholinesterase inhibiting alkaloids in Amaryllidaceae tribe Galantheae. Biochem Syst Ecol 2010; 38: 1026-1034.
34. Hohmann J, et al,. Antiproliferative Amaryllidaceae alkaloids isolated from the bulbs of Sprekelia formosissima and Hymenocallis x festalis. Planta Med 2002; 68: 454-457.
35. Luheshi LM, et al,. Systematic in vivo analysis of the intrinsic determinants of amyloid beta pathogenicity. PLoS Biol 2007; 5: e290.
36. Didziapetris R, et al,. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003; 11: 391-406.
37. Summerfield SG, et al,. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J Pharmacol Exp Ther 2007; 322: 205-213.
38. Löscher W, Potschka H,. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2006; 6: 591-602.